Trial Profile
A TRIAL OF INHALED NEBULISED UNFRACTIONATED HEPARIN SODIUM IN PATIENTS WITH STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2016
Price :
$35
*
At a glance
- Drugs Heparin (Primary)
- Indications Chronic obstructive pulmonary disease; Embolism and thrombosis
- Focus Therapeutic Use
- 08 Apr 2016 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
- 11 Feb 2016 Results (n = 24) were published in an Ockham Biotech media release.
- 14 Mar 2012 New trial record